FDA Asks for More Data on AstraZeneca PLC’s (JOBS) Symbicort

April 6, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

AP -- Drug maker AstraZeneca PLC faces a delay in marketing its asthma treatment Symbicort for young children in the United States after regulators on Monday requested more information about the drug.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

AstraZeneca Food and Drug Administration (FDA)